Registro:

Referencias:

• Crawford, Y., Ferrara, N., VEGF inhibition: Insights from preclinical and clinical studies (2009) Cell Tissue Res, 335, pp. 261-269
• Folkman, J., Shing, Y., Angiogenesis (1992) J Biol Chem, 267, pp. 10931-10934
• Folkman, J., Browder, T., Palmblad, J., Angiogenesis research: Guidelines for translation to clinical application (2001) Thrombosis and Haemostasis, 86 (1), pp. 23-33
• Arafah, B.M., Nasrallah, M.P., Pituitary tumors: Pathophysiology, clinical manifestations and management (2001) Endocrine-Related Cancer, 8 (4), pp. 287-305. , DOI 10.1677/erc.0.0080287
• Melmed, S., Pathogenesis of pituitary tumors (1999) Endocrinology and Metabolism Clinics of North America, 28 (1), pp. 1-12. , DOI 10.1016/S0889-8529(05)70055-4
• Ludecke, D.K., Buchfelder, M., Fahlbusch, R., Quabbe, H.-J., Petersenn, S., Saeger, W., Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry (2007) European Journal of Endocrinology, 156 (2), pp. 203-216. , DOI 10.1530/eje.1.02326
• Pizarro, C.B., Oliveira, M.C., Pereira-Lima, J.F., Leães, C.G., Kramer, C.K., Schuch, T., Barbosa-Coutinho, L.M., Ferreira, N.P., Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker (2009) Neuropathology, 29, pp. 40-44
• Schechter, J., Ultrastructural changes in the capillary bed of human pituitary tumors (1972) American Journal of Pathology, 67, pp. 109-126
• Turner, H.E., Nagy, Z., Gatter, K.C., Esiri, M.M., Harris, A.L., Wass, J.A.H., Angiogenesis in pituitary adenomas and the normal pituitary gland (2000) Journal of Clinical Endocrinology and Metabolism, 85 (3), pp. 1159-1162. , DOI 10.1210/jc.85.3.1159
• Ciccarelli, A., Daly, A.F., Beckers, A., The epidemiology of prolactinomas (2005) Pituitary, 8 (1), pp. 3-6. , DOI 10.1007/s11102-005-5079-0, Special Issie on Pathogenesis, Diagnosis and Clinics of Prolactinomas
• Vasilev, V., Daly, A.F., Vroonen, L., Zacharieva, S., Beckers, A., Resistant prolactinomas (2011) J Endocrinol Invest, 34, pp. 312-316
• Oh, M.C., Aghi, M.K., Dopamine agonist-resistant prolactinomas (2011) J Neurosurg, 114, pp. 1369-1379
• Gurlek, A., Karavitaki, N., Ansorge, O., Wass, J.A.H., What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics (2007) European Journal of Endocrinology, 156 (2), pp. 143-153. , DOI 10.1530/eje.1.02339
• Heaney, A.P., Fernando, M., Melmed, S., Functional role of estrogen in pituitary tumor pathogenesis (2002) Journal of Clinical Investigation, 109 (2), pp. 277-283. , DOI 10.1172/JCI200214264
• Heaney, A.P., Horwitz, G.A., Wang, Z., Singson, R., Melmed, S., Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis (1999) Nature Medicine, 5 (11), pp. 1317-1321. , DOI 10.1038/15275
• Sarkar, D.K., Genesis of prolactinomas: Studies using estrogen-treated animals (2006) Frontiers of Hormone Research, 35, pp. 32-49. , DOI 10.1159/000094307, Pituitary Today: Molecular, Physiological and Clinical Aspects
• Elias, K.A., Weiner, R.I., Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors (1984) Proceedings of the National Academy of Sciences of the United States of America, 81 (14 I), pp. 4549-4553
• Elias, K.A., Weiner, R.I., Inhibition of estrogen-induced anterior pituitary enlargement and arteriogenesis by bromocriptine in Fischer 344 rats (1987) Endocrinology, 120 (2), pp. 617-621
• Takechi, A., Effect of angiogenesis inhibitor TNP-470 on vascular formation in pituitary tumors induced by estrogen in rats (1994) Neurologia Medico-Chirurgica, 34 (11), pp. 729-733
• Luque, G.M., Perez-Millán, M.I., Ornstein, A.M., Cristina, C., Becu-Villalobos, D., Inhibitory effects of anti-VEGF strategies in experimental dopamine resistant prolactinomas (2011) J Pharmacol Exp Ther, 337, pp. 766-774
• Burris III, H., Rocha-Lima, C., New therapeutic directions for advanced pancreatic cancer: Targeting the epidermal growth factor and vascular endothelial growth factor pathways (2008) Oncologist, 13 (3), pp. 289-298. , http://theoncologist.alphamedpress.org/cgi/reprint/13/3/289, DOI 10.1634/theoncologist.2007-0134
• Kerbel, R.S., Tumor angiogenesis (2008) New England Journal of Medicine, 358 (19), pp. 2039-2049. , http://content.nejm.org/cgi/reprint/358/19/2039.pdf, DOI 10.1056/NEJMra0706596
• Haviv, F., Bradley, M.F., Kalvin, D.M., Schneider, A.J., Davidson, D.J., Majest, S.M., McKay, L.M., Henkin, J., Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: Design, synthesis, and optimization of pharmacokinetics and biological activities (2005) Journal of Medicinal Chemistry, 48 (8), pp. 2838-2846. , DOI 10.1021/jm0401560
• Lawler, J., Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth (2002) Journal of Cellular and Molecular Medicine, 6 (1), pp. 1-12
• Anderson, J.C., Grammer, J.R., Wang, W., Nabors, L.B., Henkin, J., Stewart Jr., J.E., Gladson, C.L., ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis (2007) Cancer Biology and Therapy, 6 (3), pp. 454-462. , http://www.landesbioscience.com/journals/cbt/article/anderson6-3.pdf
• Yang, Q., Tian, Y., Liu, S., Zeine, R., Chlenski, A., Salwen, H.R., Henkin, J., Cohn, S.L., Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma (2007) Cancer Research, 67 (4), pp. 1716-1724. , DOI 10.1158/0008-5472.CAN-06-2595
• Garside, S.A., Henkin, J., Morris, K.D., Norvell, S.M., Thomas, F.H., Fraser, H.M., A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early- antral follicles in vivo (2010) Endocrinology, 151, pp. 5905-5915
• Burns, G., Sarkar, D.K., Transforming growth factor-β 1-like immunoreactivity in the pituitary gland of the rat: Effect of estrogen (1993) Endocrinology, 133 (3), pp. 1444-1449. , DOI 10.1210/en.133.3.1444
• Sarkar, A.J., Chaturvedi, K., Chen, C.P., Sarkar, D.K., Changes in thrombospondin-1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumors (2007) Journal of Endocrinology, 192 (2), pp. 395-403. , DOI 10.1677/joe.1.06925
• Schultz-Cherry, S., Ribeiro, S., Gentry, L., Murphy-Ullrich, J.E., Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system (1994) Journal of Biological Chemistry, 269 (43), pp. 26775-26782
• Rifkin, D.B., Latent transforming growth factor-β (TGF-β) binding proteins: Orchestrators of TGF-β availability (2005) Journal of Biological Chemistry, 280 (9), pp. 7409-7412. , DOI 10.1074/jbc.R400029200
• Mehra, A., Wrana, J.L., TGF-β and the Smad signal transduction pathway (2002) Biochemistry and Cell Biology, 80 (5), pp. 605-622. , DOI 10.1139/o02-161
• Sarkar, D.K., Kim, K.H., Minami, S., Transforming growth factor-β1 messenger RNA and protein expression in the pituitary gland: Its action on prolactin secretion and lactotropic growth (1992) Mol Endocrinol, 6, pp. 1825-1833
• De, A., Morgan, T.E., Speth, R.C., Boyadjieva, N., Sarkar, D.K., Pituitary lactotrope expresses transforming growth factor β (TGF-β) type II receptor mRNA and protein and contains I-TGF-β1 binding sites (1995) J Endocrinol, 149, pp. 19-27
• Pastorcic, M., De, A., Boyadjieva, N., Vale, W., Sarkar, D.K., Reduction in the expression and action of transforming growth factor-β1 on lactotropes during estrogen-induced tumorigenesis (1995) Cancer Res, 55, pp. 4892-4898
• Recouvreux, M.V., Guida, M.C., Rifkin, D.B., Becu-Villalobos, D., Díaz-Torga, G., Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary (2011) Endocrinology, 152, pp. 2722-2730
• Guo, N.-H., Krutzsch, H.C., Inman, J.K., Shannon, C.S., Roberts, D.D., Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1 (1997) Journal of Peptide Research, 50 (3), pp. 210-221
• Ebbinghaus, S., Hussain, M., Tannir, N., Gordon, M., Desai, A.A., Knight, R.A., Humerickhouse, R.A., Figlin, R., Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma (2007) Clinical Cancer Research, 13 (22), pp. 6689-6695. , http://clincancerres.aacrjournals.org/cgi/reprint/13/22/6689, DOI 10.1158/1078-0432.CCR-07-1477
• Markovic, S.N., Suman, V.J., Rao, R.A., Ingle, J.N., Kaur, J.S., Erickson, L.A., Pitot, H.C., Creagan, E.T., A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma (2007) American Journal of Clinical Oncology: Cancer Clinical Trials, 30 (3), pp. 303-309. , DOI 10.1097/01.coc.0000256104.80089.35, PII 0000042120070600000016
• Gordon, M.S., Mendelson, D., Carr, R., Knight, R.A., Humerickhouse, R.A., Iannone, M., Stopeck, A.T., A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer (2008) Cancer, 113, pp. 3420-3429
• Nabors, L.B., Fiveash, J.B., Markert, J.M., Kekan, M.S., Gillespie, G.Y., Huang, Z., Johnson, M.J., Fathallah-Shaykh, H.M., A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma (2010) Arch Neurol, 67, pp. 313-319
• Campbell, N., Greenaway, J., Henkin, J., Petrik, J., ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer (2011) Mol Cancer Ther, 10, pp. 1876-1885
• Hasan, J., Byers, R., Jayson, G.C., Intra-tumoural microvessel density in human solid tumours (2002) British Journal of Cancer, 86 (10), pp. 1566-1577. , DOI 10.1038/sj.bjc.6600315
• Lloyd, R.V., Scheithauer, B.W., Kuroki, T., Vidal, S., Kovacs, K., Stefaneanu, L., Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas (1999) Endocr Pathol, 10, pp. 229-235
• McCabe, C.J., Boelaert, K., Tannahill, L.A., Heaney, A.P., Stratford, A.L., Khaira, J.S., Hussain, S., Gittoes, N.J., Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors (2002) J Clin Endocrinol Metab, 87, pp. 4238-4244
• Cristina, C., Diaz-Torga, G., Baldi, A., Gongora, A., Rubinstein, M., Low, M.J., Becu-Villalobos, D., Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice (2005) Endocrinology, 146 (7), pp. 2952-2962. , http://endo.endojournals.org/cgi/reprint/146/7/2952, DOI 10.1210/en.2004-1445
• Cristina, C., Tornadú, I.G., Millán, M.I.P., Díaz-Torga, G., Becu-Villalobos, D., Factores de crecimiento y antiangiogenesis en prolactinomas resistentes a dopamina (2006) Anales de la Academia Nacional de Ciencias, 39, pp. 1-15. , Buenos Aires
• Mallea-Gil, M.S., Cristina, C., Perez-Millan, M.I., Villafañe, A.M., Ballarino, C., Stalldecker, G., Becu-Villalobos, D., Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers (2009) Endocr Pathol, 20, pp. 35-50
• Cristina, C., Perez-Millan, M.I., Luque, G., Dulce, R.A., Sevlever, G., Berner, S.I., Becu-Villalobos, D., VEGF and CD31 association in pituitary adenomas (2010) Endocr Pathol, 21, pp. 154-160
• Turner, H.E., Nagy, Z.., Gatter, K.C., Esiri, M.M., Harris, A.L., Wass, J.A.H., Angiogenesis in pituitary adenomas - Relationship to endocrine function, treatment and outcome (2000) Journal of Endocrinology, 165 (2), pp. 475-481
• Febbraio, M., Hajjar, D.P., Silverstein, R.L., CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism (2001) Journal of Clinical Investigation, 108 (6), pp. 785-791. , DOI 10.1172/JCI200114006
• Rice, C., Huang, L.E., From antiangiogenesis to hypoxia: Current research and future directions (2010) Cancer Manag Res, 3, pp. 9-16
• Campbell, N.E., Greenaway, J., Henkin, J., Moorehead, R.A., Petrik, J., The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer (2010) Neoplasia, 12, pp. 275-283
• Sarkar, D.K., Pastorcic, M., De, A., Engel, M., Moses, H., Ghasemzadeh, M.B., Role of transforming growth factor (TGF)-β type I and TGF-β type II receptors in the TGF-β1-regulated gene expression in pituitary prolactin- secreting lactotropes (1998) Endocrinology, 139 (8), pp. 3620-3628. , DOI 10.1210/en.139.8.3620
• Yoshinaga, K., Obata, H., Jurukovski, V., Mazzieri, R., Chen, Y., Zilberberg, L., Huso, D., Rifkin, D.B., Perturbation of transforming growth factor (TGF)-β1 association with latent TGF-β binding protein yields inflammation and tumors (2008) Proc Natl Acad Sci USA, 105, pp. 18758-18763
• Silverstein, R.L., Febbraio, M., CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior (2009) Sci Signal, 2, pp. re3
• Young, G.D., Murphy-Ullrich, J.E., The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-β complex (2004) Journal of Biological Chemistry, 279 (46), pp. 47633-47642. , DOI 10.1074/jbc.M404918200
• Miyazono, K., Heldin, C.H., Latent forms of TGF-β: Molecular structure and mechanisms of activation (1991) Ciba Found Symp, 157, pp. 81-89. , discussion 89-92
• Taipale, J., Miyazono, K., Heldin, C.-H., Keski-Oja, J., Latent transforming growth factor-β1 associates to fibroblast extracellular matrix via latent TGF-β binding protein (1994) Journal of Cell Biology, 124 (1-2), pp. 171-181
• Taipale, J., Saharinen, J., Hedman, K., Keski-Oja, J., Latent transforming growth factor-β1 and its binding protein are components of extracellular matrix microfibrils (1996) Journal of Histochemistry and Cytochemistry, 44 (8), pp. 875-889
• Koski, C., Saharinen, J., Keski-Oja, J., Independent promoters regulate the expression of two amino terminally distinct forms of latent transforming growth factor-β binding protein-1 (LTBP-1) in a cell type-specific manner (1999) Journal of Biological Chemistry, 274 (46), pp. 32619-32630
• Weikkolainen, K., Keski-Oja, J., Koli, K., Expression of latent TGF-β binding protein LTBP-1 is hormonally regulated in normal and transformed human lung fibroblasts (2003) Growth Factors, 21 (2), pp. 51-60. , DOI 10.1080/08977198310001598778

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------